Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: A post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients

Clinical Therapeutics

Volumn 31, Issue 1, 2009, Pages 115-122

  Bays, Harold E ^a   Maccubbin, Darbie ^b   Meehan, Alan G ^b   Kuznetsova, Olga ^b   Mitchel, Yale B ^b   Paolini, John F ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

diastolic blood pressure; dyslipidemia; laropiprant; niacin; systolic blood pressure

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; NICOTINIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; BLOOD PRESSURE; CLINICAL TRIALS, PHASE III AS TOPIC; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; INDOLES; MALE; MIDDLE AGED; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 60449103180     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.01.010     Document Type: Article

References (12)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
2. Capuzzi D.M., Guyton J.R., Morgan J.M., et al. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. Am J Cardiol 82 (1998) 74U-81 U discussion 85U-86U.
3. Morgan J.M., Capuzzi D.M., and Guyton J.R. A new extended-release niacin (Niaspan): Efficacy, tolerabihty, and safety in hypercholesterolemic patients. Am J Cardiol 82 (1998) 29U-34U discussion 39U-41U
4. Bays H.E. Extended-release niacin/lovastatin: The first combination product for dyshpidemia. Expert Rev Cardiovasc Ther 2 (2004) 485-501
5. Kamal-Bahl S.J., Burke T., Watson D., and Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 99 (2007) 530-534
6. Cheng K., Wu T.J., Wu K.K., et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 103 (2006) 6682-6687
7. Kaijser L., Eklund B., Olsson A.G., and Carlson L.A. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 57 (1979) 114-117
8. Maccubbin D., Bays H.E., Olsson A.G., et al. Lipid-modifying efficacy and tolerabihty of extended-release niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyshpidemia. Int J Clin Prac 62 (2008) 1959-1970
9. Paolini J.P., Mitchel Y.B., Reyes R., et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyshpidemia. Am J Cardiol 101 (2008) 625-630
10. Canner P.L., Furberg C.D., and McGovern M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 97 (2006) 477-479
11. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
12. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255